Personal information

No personal information available

Activities

Collapse all

Works (37)

Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases

Journal of Clinical Oncology
2025-03-06 | Journal article
DOI: 10.1200/JCO-24-02219
Contributors: Sarah A. Weiss; Dijana Djureinovic; Wei Wei; Thuy Tran; Matthew Austin; Joseph Markowitz; Zeynep Eroglu; Nikhil I. Khushalani; Upendra Hegde; Justine Cohen et al.
Source: check_circle
Crossref

Data from Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma

2024-12-02 | Preprint
DOI: 10.1158/1078-0432.c.7565428
Contributors: Ahmad A. Tarhini; Zeynep Eroglu; Islam Eljilany; Jonathan S. Zager; Ricardo J. Gonzalez; Amod A. Sarnaik; Carl Wayne Cruse; Nikhil I. Khushalani; Deanryan B. De Aquino; Edith Abraham et al.
Source: check_circle
Crossref

Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma

Clinical Cancer Research
2024-12-02 | Journal article
DOI: 10.1158/1078-0432.CCR-24-2768
Contributors: Ahmad A. Tarhini; Zeynep Eroglu; Islam Eljilany; Jonathan S. Zager; Ricardo J. Gonzalez; Amod A. Sarnaik; Carl Wayne Cruse; Nikhil I. Khushalani; Deanryan B. De Aquino; Edith Abraham et al.
Source: check_circle
Crossref

Supplementary Table S1 from Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma

2024-12-02 | Preprint
DOI: 10.1158/1078-0432.27938158
Contributors: Ahmad A. Tarhini; Zeynep Eroglu; Islam Eljilany; Jonathan S. Zager; Ricardo J. Gonzalez; Amod A. Sarnaik; Carl Wayne Cruse; Nikhil I. Khushalani; Deanryan B. De Aquino; Edith Abraham et al.
Source: check_circle
Crossref

Supplementary Table S2 from Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma

2024-12-02 | Preprint
DOI: 10.1158/1078-0432.27938155
Contributors: Ahmad A. Tarhini; Zeynep Eroglu; Islam Eljilany; Jonathan S. Zager; Ricardo J. Gonzalez; Amod A. Sarnaik; Carl Wayne Cruse; Nikhil I. Khushalani; Deanryan B. De Aquino; Edith Abraham et al.
Source: check_circle
Crossref

Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma

Journal for ImmunoTherapy of Cancer
2024-09 | Journal article
DOI: 10.1136/jitc-2024-009816
Contributors: Tanya Ramadoss; Matthew Nichols; Christian Palacios; Zeynep Eroglu; Joseph Markowitz; Lilit Karapetyan; Ahmad A Tarhini; Evan J Wuthrick; Vernon K Sondak; Nikhil I Khushalani et al.
Source: check_circle
Crossref

Data from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.c.7380259.v1
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Data from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.c.7380259
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Molecular Cancer Therapeutics
2024-08-01 | Journal article
DOI: 10.1158/1535-7163.MCT-23-0652
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 1 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423974
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 1 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423974.v1
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423971.v1
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423971
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 3 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423968
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 3 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423968.v1
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 4 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423965.v1
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 4 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423965
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 5 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423962
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 5 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423962.v1
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 6 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423959.v1
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 6 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423959
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 7 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423956
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 7 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423956.v1
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 8 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423953
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Figure 8 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423953.v1
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Table 1 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423950.v1
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Table 1 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423950
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Table 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423944.v1
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Supplemental Table 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

2024-08-01 | Preprint
DOI: 10.1158/1535-7163.26423944
Contributors: Joseph Markowitz; Michael Shamblott; Andrew S. Brohl; Amod A. Sarnaik; Zeynep Eroglu; Nikhil I. Khushalani; Christopher W. Dukes; Alejandra Chamizo; Marina Bastawrous; Edward T. Garcia et al.
Source: check_circle
Crossref

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer
2024-03 | Journal article
DOI: 10.1136/jitc-2023-007364
Contributors: Nikhil I Khushalani; Patrick A Ott; Robert L Ferris; Tina Cascone; Dirk Schadendorf; Dung T Le; Manish R Sharma; Fabrice Barlesi; William Sharfman; Jason J Luke et al.
Source: check_circle
Crossref

Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers

Journal of Clinical Oncology
2024-03-20 | Journal article
DOI: 10.1200/JCO.23.01497
Contributors: Kara M. Schenk; Julie Stein Deutsch; Sunandana Chandra; Diwakar Davar; Zeynep Eroglu; Nikhil I. Khushalani; Jason J. Luke; Patrick A. Ott; Jeffrey A. Sosman; Vikram Aggarwal et al.
Source: check_circle
Crossref

Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study

Immunotherapy
2024-01 | Journal article
DOI: 10.2217/imt-2022-0292
Contributors: John M Kirkwood; Lisa A Kottschade; Robert R McWilliams; Nikhil I Khushalani; Sekwon Jang; Sigrun Hallmeyer; David F McDermott; Hussein Tawbi; Min Che; Cho-Han Lee et al.
Source: check_circle
Crossref

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

Journal for ImmunoTherapy of Cancer
2023-03 | Journal article
DOI: 10.1136/jitc-2022-005923
Contributors: Michael B Atkins; Paolo A Ascierto; David Feltquate; James L Gulley; Douglas B Johnson; Nikhil I Khushalani; Jeffrey Sosman; Timonthy A Yap; Harriet Kluger; Ryan J Sullivan et al.
Source: check_circle
Crossref

Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma

Cancer
2022-11 | Journal article
DOI: 10.1002/cncr.34449
Contributors: Vernon K. Sondak; Rogerio I. Neves; Evan J. Wuthrick; Jane L. Messina; Nikhil I. Khushalani
Source: check_circle
Crossref

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma

Journal for ImmunoTherapy of Cancer
2022-11 | Journal article
DOI: 10.1136/jitc-2022-005684
Contributors: Nikhil I Khushalani; Melinda Vassallo; Judith D Goldberg; Zeynep Eroglu; Younchul Kim; Biwei Cao; Robert Ferguson; Kelsey R Monson; Tomas Kirchhoff; Carol M Amato et al.
Source: check_circle
Crossref

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Journal of Clinical Oncology
2021-08-20 | Journal article
DOI: 10.1200/JCO.21.00612
Contributors: Amod A. Sarnaik; Omid Hamid; Nikhil I. Khushalani; Karl D. Lewis; Theresa Medina; Harriet M. Kluger; Sajeve S. Thomas; Evidio Domingo-Musibay; Anna C. Pavlick; Eric D. Whitman et al.
Source: check_circle
Crossref

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

Future Oncology
2020-10 | Journal article
DOI: 10.2217/fon-2020-0351
Contributors: Nikhil I Khushalani; Adi Diab; Paolo A Ascierto; James Larkin; Shahneen Sandhu; Mario Sznol; Henry B Koon; Anthony Jarkowski; Ming Zhou; Paul Statkevich et al.
Source: check_circle
Crossref

Peer review (15 reviews for 3 publications/grants)

Review activity for British journal of cancer. (2)
Review activity for Journal for immunotherapy of cancer. (12)
Review activity for The lancet oncology. (1)
How many people are using ORCID?